Search this site

The CRASH-3 trial is being conducted to assess the effect of tranexamic acid on risk of death or disability in patients with Traumatic Brain Injury (TBI).  TBI can cause bleeding in the brain. If left to continue, it can create pressure that can lead to further damage that will result in death or permanent disability. By conducting this trial we are collecting important evidence to help determine if tranexamic acid is an effective treatment for patients with TBI. 

The CRASH-3 trial is inspired by the results of the CRASH-2 trial. The CRASH-2 trial showed that tranexamic acid, an affordable and heat stable drug, reduced death due to bleeding and had the most beneficial effect when administered as soon as possible after injury. 

5126 patients randomised 
(last updated 28/08/2015)

  • Royal London Hospital and Lahore General Hospital (LGH) Unit II have between them, recruited over 500 patients to the trial.

    Read Post
  • This two-day course focuses on management of randomised controlled trials (RCTs). This year's course will be on Tuesday 25th November and Wednesday 26th November.

    Read Post
  • In April, Yasushi Hagihara the National Coordinator (NC) of Japan held a 2-day conference at the Senshu Trauma Critical Care Centre, Osaka to discuss the expansion of the CRASH-3 trial in Japan.

    Read Post